Last reviewed · How we verify
Cefazolin PostOperatively
Cefazolin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.
Cefazolin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Used for Surgical site infection prophylaxis (postoperative use), Bacterial infections caused by susceptible organisms.
At a glance
| Generic name | Cefazolin PostOperatively |
|---|---|
| Also known as | Ancef, Kefzol |
| Sponsor | Aultman Health Foundation |
| Drug class | First-generation cephalosporin |
| Target | Penicillin-binding proteins (PBPs) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Cefazolin works by disrupting the cross-linking of peptidoglycan in bacterial cell walls, leading to cell wall instability and bacterial death. It is bactericidal and has broad activity against gram-positive cocci and some gram-negative bacteria. When used postoperatively, it provides prophylaxis against surgical site infections.
Approved indications
- Surgical site infection prophylaxis (postoperative use)
- Bacterial infections caused by susceptible organisms
Common side effects
- Hypersensitivity reactions (rash, urticaria)
- Phlebitis at injection site
- Diarrhea
- Nausea
- Anaphylaxis
Key clinical trials
- Antibiotic Prophylaxis in Patients Undergoing Elective Total Knee Arthroplasty- Multi-center Trial (PHASE4)
- Prevention of Infections in Cardiac Surgery (NA)
- Single Dose Versus 24 Hours Antibiotic Prophylaxis in Reduction Mammaplasty (NA)
- Impact of Probiotics on Gut Microbiome During Antibiotic Prophylaxis in Elective Orthopedic Surgery (PHASE4)
- Preoperative Daptomycin Prophylaxis in Two-Stage Exchange Arthroplasty: A Prospective, Randomized, Double-Blinded Trial (NA)
- Postoperative Antibiotics Following Primary and Secondary Breast Augmentation (PHASE4)
- SSI Rates in Patients Undergoing Mastectomy Without Reconstruction- A Multicenter, Double-blinded RCT. (PHASE3)
- Prophylactic Antibiotics for Prevention of Wound Complications Following Vulvectomy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cefazolin PostOperatively CI brief — competitive landscape report
- Cefazolin PostOperatively updates RSS · CI watch RSS
- Aultman Health Foundation portfolio CI